|
|
Volumn 68, Issue 6, 2000, Pages 677-687
|
|
Clinical trial simulation of docetaxel in patients with cancer as a tool for dosage optimization
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
DOCETAXEL;
AREA UNDER THE CURVE;
ARTICLE;
ASTHENIA;
CANCER SURVIVAL;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DEATH;
DECISION MAKING;
DIARRHEA;
DOSE RESPONSE;
DRUG CLEARANCE;
DRUG EFFICACY;
DRUG SAFETY;
FEBRILE NEUTROPENIA;
FEMALE;
HUMAN;
INFECTION;
LUNG NON SMALL CELL CANCER;
MAJOR CLINICAL STUDY;
MALE;
PHASE 2 CLINICAL TRIAL;
PHASE 3 CLINICAL TRIAL;
PREDICTION;
PRIORITY JOURNAL;
PROTEIN BLOOD LEVEL;
SIMULATION;
STOMATITIS;
ADULT;
AGED;
ANTINEOPLASTIC AGENTS, PHYTOGENIC;
CARCINOMA, NON-SMALL-CELL LUNG;
CLINICAL TRIALS, PHASE II;
CLINICAL TRIALS, PHASE III;
COMPUTER SIMULATION;
DOSE-RESPONSE RELATIONSHIP, DRUG;
FEMALE;
HUMANS;
LUNG NEOPLASMS;
MALE;
MIDDLE AGED;
MODELS, BIOLOGICAL;
MULTICENTER STUDIES;
OROSOMUCOID;
PACLITAXEL;
PROGNOSIS;
PROPORTIONAL HAZARDS MODELS;
REGRESSION ANALYSIS;
REPRODUCIBILITY OF RESULTS;
SURVIVAL ANALYSIS;
TAXOIDS;
|
|
EID: 0034520354
PISSN: 00099236
EISSN: None
Source Type: Journal
DOI: 10.1067/mcp.2000.111948 Document Type: Article |
|
Times cited : (72)
|
|
References (26)
|
